{"id":8977,"date":"2004-09-06T10:44:17","date_gmt":"2004-09-06T10:44:17","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=8977"},"modified":"2014-05-22T16:43:17","modified_gmt":"2014-05-22T16:43:17","slug":"tipranavir-significantly-lowers-doses-of-saquinavir-amprenavir-and-lopinavirr","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/8977","title":{"rendered":"Tipranavir significantly lowers doses of saquinavir, amprenavir and lopinavir\/r"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Interaction data were presented again from the BI 1182.51 study using tipranavir with additional protease inhibitors in extensively PI-experienced patients.<\/strong> [1]<strong> <\/strong><\/p>\n<p>Although management of treatment-experienced patients has often included multiple-PI and boosted-PI regimens, the negative interaction of tipranavir in reducing levels of saquinavir, amprenavir and lopinavir\/r must be remembered.<\/p>\n<p>HTB reported this data in full when it was presented at the pharmacology workshop earlier this year, and no new data was added to the analysis in Bangkok. [2]<\/p>\n<p>Tipranavir is available in the UK on an expanded access programme.<\/p>\n<p>References:<\/p>\n<ol>\n<li>Walmsley S, Leith J, Katlama C et al. Pharmacokinetics and safety of tipranavir\/ritonavir (TPV\/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51. XV Intl AIDS Conference, Bangkok. Abstract WeOrB1236.<br \/>\n<a href=\"http:\/\/www.ias.se\/ejias\/show.asp?abstract_id=2166920\">http:\/\/www.ias.se\/ejias\/show.asp?abstract_id=2166920<\/a><\/li>\n<li>See HTB Vol 5 No 4, May 2004.<br \/>\n<a href=\"http:\/\/www.i-base.info\/pub\/htb\/v5\/htb5-4\/Large.html\">http:\/\/www.i-base.info\/pub\/htb\/v5\/htb5-4\/Large.html<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Interaction data were presented again from the BI 1182.51 study using tipranavir with additional protease inhibitors in extensively PI-experienced patients. [1] Although management of treatment-experienced patients has often included multiple-PI and boosted-PI regimens, the negative interaction &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,34],"tags":[150],"class_list":["post-8977","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pk-and-drug-interactions","tag-aids-15th-bangkok-2004"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/8977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=8977"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/8977\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=8977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=8977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=8977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}